1. Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening.
- Author
-
Wang Y, Law WK, Hu JS, Lin HQ, Ip TM, and Wan DC
- Subjects
- Drug Approval, Fatty Acid-Binding Proteins chemistry, Humans, Ligands, Metabolic Diseases drug therapy, Protein Conformation, Small Molecule Libraries therapeutic use, United States, Drug Discovery, Fatty Acid-Binding Proteins antagonists & inhibitors, Fatty Acid-Binding Proteins metabolism, Molecular Docking Simulation, Small Molecule Libraries metabolism, Small Molecule Libraries pharmacology, United States Food and Drug Administration
- Abstract
We first identified fluorescein, ketazolam, antrafenine, darifenacin, fosaprepitant, paliperidone, risperidone, pimozide, trovafloxacin, and levofloxacin as inhibitors of fatty acid binding protein 4 using molecular docking screening from FDA-approved drugs. Subsequently, the biochemical characterizations showed that levofloxacin directly inhibited FABP4 activity in both the in vitro ligand displacement assay and cell-based function assay. Furthermore, levofloxacin did not induce adipogenesis in adipocytes, which is the major adverse effect of FABP4 inhibitors.
- Published
- 2014
- Full Text
- View/download PDF